Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT05492474 Recruiting - Clinical trials for Acute Ischemic Stroke

Cranial Ultrasound for Prehospital ICH Diagnosis

CUPID_EMS
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the feasibility of Emergency Medical System (EMS)-performed cPOCUS in the field for diagnosis of acute Intracerebral hemorrhage (ICH)

NCT ID: NCT05492214 Active, not recruiting - Blood Loss Clinical Trials

The Effect of Time Window for Umbilical Cord Clamping During Cesareans on Offspring Hemoglobin and Maternal Blood Loss

Start date: September 22, 2022
Phase: N/A
Study type: Interventional

This is a randomized controlled trial, aiming to evaluate the effects of time window for umbilical cord clamping during cesarean section on the health outcomes of offspring hemoglobin,maternal blood loss,and children's growth and development. It will be conducted in Liuyang city and Huantai county of China, and the targeted sample size is 360 (180 in each site). All the eligible pregnant women will be randomly assigned to one of the four groups (three intervention groups and one control group), and their babies will be followed up to 18 months of age.

NCT ID: NCT05491980 Recruiting - Ischemic Stroke Clinical Trials

Florida Cerebrovascular Disease Biorepository and Genomics Center

Start date: August 2, 2022
Phase:
Study type: Observational

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

NCT ID: NCT05491356 Recruiting - Hematoma, Subdural Clinical Trials

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Start date: May 11, 2023
Phase: Phase 4
Study type: Interventional

To determine the utility of tissue plasminogen activator (tPA) in the clearance of chronic subdural hematomas (CSDH). Intra-catheter tPA will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.

NCT ID: NCT05490173 Not yet recruiting - Premature Birth Clinical Trials

The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

To study the safety and efficacy of intranasal administration of exosomes derived from mesenchymal stromal cells on long-term neurodevelopmental outcome in extremely low birth weight infants born at gestational age 25/0-27/6 weeks.

NCT ID: NCT05489185 Not yet recruiting - Hip Fractures Clinical Trials

Clinical Trial to Assess the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients.

Start date: May 30, 2023
Phase: Phase 4
Study type: Interventional

Hip fracture in elderly patients is a pathology with a high economic and health impact on the patient himself and on the National Health System, especially considering the significant aging of the population of the Basque Country. Despite advances, hip fracture remains in the clinical groups with the highest in-hospital mortality. Hip fracture is associated with numerous adverse events and high mortality. Numerous antifibrinolytics, such as tranexamic acid (TXA), have been used to limit bleeding in orthopedic surgery and thus prevent the need for blood transfusion. Numerous studies have shown that the use of tranexamic acid does not increase the risk of thrombosis. It is proposed to carry out clinical research with drugs without commercial interest. A randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in elderly patients with hip fracture.

NCT ID: NCT05488457 Not yet recruiting - Clinical trials for Cesarean Section Complications

Oxytocin Pharmacokinetics and Pharmacodynamics

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus. After delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship. The goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.

NCT ID: NCT05483751 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia

PDMMS
Start date: January 1, 2023
Phase:
Study type: Observational

Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) results from a complex combination of macro- and microvascular processes. Besides cerebral vasospasms (CVS), DCI is caused by microthrombosis, neuroinflammation, microvascular dysfunction and cortical spreading depolarization.The glycocalyx plays an essential role in regulation of inflammation, oxidative stress and thrombosis, and could be involved in the pathophysiology of DCI. This study is a single-center prospective observational pilot (phase 1) and correlation (phase 2) study recruiting patients with an aneurysmal subarachnoid hemorrhage. The primary aim of the study is to evaluate the feasibility of performing measurements of the glycocalyx using side-stream darkfield (SDF) imaging sublingually and on the conjunctiva, and by sampling blood for analysis of markers of glycocalyx shedding. Moreover, the objective is to determine characteristic Doppler waveform morphologies in DCI patients by means of thorough analysis of transcranial Doppler (TCD) measurements. The secondary objective is to determine whether changes in glycocalyx integrity correlate with the development of DCI and whether these changes are associated with increased inflammation and with variation in TCD signals. Finally, changes in glycocalyx integrity, in TCD waveform morphology and in levels of inflammatory markers will be correlated with patient outcome at 6 weeks and 6 months after ictus.

NCT ID: NCT05483348 Completed - Uterine Bleeding Clinical Trials

Clinical Predictive Factors of Success of Hysteroscopic Endometrial Ablation/Resection

Start date: February 17, 2022
Phase:
Study type: Observational

To determine the predictive factors of endometrial ablation failure in the management of uterine bleeding.

NCT ID: NCT05479357 Not yet recruiting - High Risk Pregnancy Clinical Trials

Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

Comparison between Carbetocin and Oxytocin as prophylaxis against Primary Postpartum Hemorrhage.